CPPs can deliver PNAs and siRNAs into cells to inhibit hepatitis B virus replication and antigen expression, overcoming the major barrier of poor intracellular bioavailability.
CPPs solve delivery barrierPNAs and siRNAs inhibit HBV but cannot enter cells alone — CPP conjugation enables intracellular delivery
What the researchers found
CPP-conjugated PNAs and siRNAs can inhibit hepatitis B virus replication and antigen expression, with CPPs solving the critical intracellular delivery challenge for oligonucleotide-based antivirals.
Why it matters
Chronic hepatitis B affects ~300 million people with no cure. CPP-delivered gene-silencing therapies could offer a functional cure by targeting viral genes that current drugs cannot reach.
The numbers in context
PNAs reduced hepadnaviral replication; siRNAs inhibited HBV antigens; CPP conjugation improves delivery
How the study worked
Review of PNA and siRNA anti-HBV approaches, including original data on PNA-mediated inhibition in duck HBV model and discussion of CPP delivery strategies.
Who was studied
Review of CPP-mediated delivery of PNAs and siRNAs for hepatitis B virus treatment
What this study cannot tell us
Largely preclinical with duck HBV model and cell culture; in-vivo human liver delivery remains challenging; CPP-oligonucleotide stability and toxicity need further assessment.
How to read the evidence
Review with supporting preclinical data (duck HBV model, cell culture); human in-vivo evidence is lacking and liver-specific delivery remains a challenge.
When this study was published
Published in 2020; HBV cure research has since advanced with multiple gene-silencing approaches in clinical trials.
The bigger picture
This approach exemplifies the convergence of gene therapy and peptide delivery — using CPPs to enable a new class of antiviral medicines that silence viral genes directly.
Questions still open
- Can CPP-PNA or CPP-siRNA conjugates achieve therapeutic concentrations in human liver in vivo?
- How do CPP-delivered antivirals compare to newer HBV drugs in development like capsid inhibitors?
- Could this approach achieve functional cure (HBsAg loss) for chronic HBV?
Common questions
Can gene-silencing treat hepatitis B?
Why is hepatitis B hard to cure?
Read the original research
Cell Penetrating Peptides Used in Delivery of Therapeutic Oligonucleotides Targeting Hepatitis B Virus.
Pharmaceuticals (Basel, Switzerland), 13(12)
Citation
Ndeboko, Bénédicte; Omouessi, Serge Thierry; Ongali, Brice; Mouinga-Ondémé, Augustin. (2020). Cell Penetrating Peptides Used in Delivery of Therapeutic Oligonucleotides Targeting Hepatitis B Virus.. Pharmaceuticals (Basel, Switzerland), 13(12). https://doi.org/10.3390/ph13120483